Diabetic Drugs Linked to Fournier's Gangrene May Treat Heart Conditions

Diabetes Drug Infection Lawsuit News

Anti-diabetes drugs called sodium glucose blockers or SGLT2 drugs are showing promise to treat more diseases than just diabetes

Wednesday, January 29, 2020 - Cath Labs Digest reports that the FDA has granted a priority review of another SGLT2 drug for a dual purpose. According to the publication, "AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D)." SGLT2 drugs are warned to have the side effect of weakening one's immune system where the body can be susceptible to necrotizing fasciitis that can enter through any break in the skin in the perineum area in between the anus and scrotum. Diabetes drug infection lawsuit attorneys representing people harmed from necrotizing fasciitis and offer a free consultation with no obligation to file a claim.

Diabetics are required to inject themselves at least daily with insulin to regulate their blood sugar levels but patients also have the alternative of taking an SGLT2 drug if they do not wish to do so. SGLT2 drugs re-route sugar out of the bloodstream through the urine, bypassing the kidneys. Sodium-glucose blocker drugs have been linked to over 50 cases of Fournier's Gangrene, an insidious and frightening flesh-eating condition affecting the genitals and often requiring genital mutilation surgery or genital amputation. People that have developed Fournier's Gangrene have consulted with Fournier's Gangrene attorneys to determine if they qualify to hold the makers of the drug accountable for failing to warn them of the possibilities of contracting the disease.

Mene Pangalos, Executive Vice President, BioPharmaceuticals is optimistic for the future of the drug and recently told Cath Labs Digest: "FARXIGA is well established in the treatment of type 2 diabetes and this Priority Review shows its potential to also impact millions of patients with heart failure. If approved, FARXIGA will be the first and only medicine of its kind indicated to treat patients with heart failure." FARXIGA is intended to be used in combination with a program of improved diet and exercise.

FARXIGA carries some of the most serious drug warnings of any drug on the market. FARXIGA causes hypertension, ketoacidosis, acute kidney injury, and above all Fournier's Gangrene, a rare but deadly form of flesh-rotting disease of the perineum. Fournier's Gangrene is a life-threatening condition that affects both men and women but mostly men. According to the drug's manufacturer, Fournier's Gangrene can cause "Serious outcomes including hospitalization, surgeries, and death." Early warning signs of Fourniers are pain, tenderness, edema and swelling in the genital or perineal area, lethargy and fever and Forixiga should be discontinued if these symptoms occur. It is critical to seek immediate professional medical attention as Fournier's Gangrene can spread rapidly. The disease is usually treated with surgery to stop the spread much like back burning is done to halt the spread of a wildfire. Patients are given broad-spectrum antibiotics intravenously as well as packed into the surgical wound. A patient with Fournier's Gangrene usually spends around 3 to months in the hospital.

More Recent Diabetes Drug Infection Lawsuit News:

Lawyers for Fournier's Gangrene

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.